Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BRI-1501 vs Lafutidine and Irsogladine in Healthy Volunteers
NCT02759224Phase 1Completed
- Sponsor
- Boryung
- Start
- Apr 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of irsogladine + lafutidine in gastric ulcer (2 arms), sponsored by Boryung. Primary endpoints: Maximum observed concentration and Area under the plasma drug concentration-time curve. Started Apr 2016; status: completed.
02
Drugs
irsogladine + lafutidine
03
Conditions
gastric ulcer
Beyond the preview
Go deeper on NCT02759224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02759224.